Last reviewed · How we verify
NCT00324545
Cardiovascular Outcomes Of Diet Counseling
Phase 3 trial testing Medium-intensity Minimally-directive Counseling in Coronary Artery Disease in 120 participants. Completed in 31 December 2002.
31 December 2002
Quick facts
| Lead sponsor | The Camelot Foundation |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 January 2000 |
| Primary completion | 31 December 2002 |
| Estimated completion | 31 December 2002 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Medium-intensity Minimally-directive Counseling
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Obesity — all drugs for Obesity →
Sponsor
The Camelot Foundation
Who can join
Adults 30 to 59, any sex, with Coronary Artery Disease or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
(1) What effect does behavioral counseling for vegan, for low to moderate fat, and for lowered carbohydrate diets have on coronary blood flow? (2) What are the effects of different diet protocols when caloric intake and exercise are equalized? (3) Do people, so counseled, maintain their modified behaviors after they have completed their diet program? (4) How does targeting different diets affect secondary indices associated with heart disease such as weight, lipid, inflammatory, and thrombotic factors?
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases.
Rees K, Al-Khudairy L, Takeda A, Stranges S. · · 2021 · cited 26× · PMID 33629376 · DOI 10.1002/14651858.cd013501.pub2
Verify or expand the search:
- PubMed search for NCT00324545
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other The Camelot Foundation trials
Trials by the same sponsor.
- NCT04349410 — The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00324545 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Camelot Foundation
- Last refreshed: 21 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00324545.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing